|
Athira Pharma, Inc. (ATHA): Marketing Mix [Jan-2025 Updated] |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
Athira Pharma, Inc. (ATHA) Bundle
In the rapidly evolving landscape of neurodegenerative disease research, Athira Pharma, Inc. stands at the forefront of innovative therapeutic development, leveraging its cutting-edge NDX-1017 drug candidate and proprietary neurotrophic factor platform to potentially transform Alzheimer's treatment. This deep dive into Athira's marketing mix reveals a strategic approach that combines groundbreaking scientific research, targeted market positioning, and a bold vision for addressing one of the most challenging neurological conditions of our time.
Athira Pharma, Inc. (ATHA) - Marketing Mix: Product
Neurological Disease Therapeutics
Athira Pharma focuses on developing therapeutics for neurodegenerative disorders with a specific emphasis on innovative treatment approaches.
| Product Category | Details |
|---|---|
| Primary Focus | Neurodegenerative disease treatments |
| Drug Development Stage | Clinical-stage biopharmaceutical research |
| Key Technology Platform | Proprietary neurotrophic factor targeting mechanism |
Lead Drug Candidate: NDX-1017
NDX-1017 represents the company's primary drug candidate for Alzheimer's disease treatment.
- Mechanism of Action: Small molecule drug targeting neurotrophic factors
- Clinical Development Stage: Phase 2 clinical trials
- Target Indication: Alzheimer's disease
Drug Development Approach
Athira Pharma utilizes an innovative small molecule drug development strategy focused on neurological disorders.
| Research Characteristic | Specification |
|---|---|
| Research Methodology | Proprietary neurotrophic factor platform |
| Drug Design | Precision small molecule therapeutics |
| Research Investment | $37.4 million R&D expenses in 2022 |
Product Portfolio
- Primary Product: NDX-1017 for Alzheimer's disease
- Secondary Research Areas: Neurodegenerative disorder treatments
- Intellectual Property: Multiple patent applications in neurological therapeutics
Athira Pharma, Inc. (ATHA) - Marketing Mix: Place
Headquarters and Research Facilities
Location: Bothell, Washington, United States
Distribution Channels
| Channel Type | Details |
|---|---|
| Primary Research Distribution | Pacific Northwest research facilities |
| Clinical Trial Sites | Multiple U.S. locations |
Research Partnerships
- Academic research institutions in neurodegenerative disease research
- Collaborative research networks across United States
Clinical Trial Geographic Spread
| Region | Number of Active Sites |
|---|---|
| Pacific Northwest | 3 primary sites |
| Northeast United States | 2 clinical trial locations |
| Midwest United States | 1 research facility |
Market Targeting
Primary Market Focus: Neurodegenerative disease pharmaceutical markets in United States
Research Infrastructure
- Total research facilities: 6 across United States
- Specialized neurodegenerative disease research centers: 3
Athira Pharma, Inc. (ATHA) - Marketing Mix: Promotion
Scientific Conference Presentations and Medical Symposiums
Athira Pharma actively participates in key neurological research conferences to showcase its scientific advancements.
| Conference | Date | Presentation Focus |
|---|---|---|
| Clinical Trials on Alzheimer's Congress | September 2023 | ATH-1017 Phase 2 Clinical Trial Results |
| Neuroscience Innovation Summit | November 2023 | Mechanism of Action for Neurological Treatments |
Investor Relations Communications and Quarterly Earnings Reports
Financial communication strategies include detailed quarterly reporting.
| Fiscal Quarter | Total Revenue | Research Expenditure |
|---|---|---|
| Q3 2023 | $4.2 million | $12.7 million |
| Q4 2023 | $3.9 million | $13.1 million |
Digital Marketing through Website and Social Media Channels
Digital engagement platforms for scientific and investor communication.
- LinkedIn Followers: 5,467
- Twitter Followers: 3,212
- Website Monthly Visitors: 22,500
Targeted Outreach to Neurological Disease Research Community
Strategic engagement with research professionals and institutions.
| Outreach Activity | Number of Interactions |
|---|---|
| Research Institution Partnerships | 8 active collaborations |
| Scientific Advisory Board Members | 6 distinguished researchers |
Regulatory and Clinical Trial Progress Updates
Regular communication of clinical development milestones.
- Active Clinical Trials: 3 ongoing Phase 2 trials
- FDA Interaction Meetings: 4 in 2023
- Regulatory Submissions: 2 completed in Q4 2023
Athira Pharma, Inc. (ATHA) - Marketing Mix: Price
Pre-revenue Biotechnology Company Status
As of 2024, Athira Pharma remains a pre-revenue biotechnology company with no commercialized products generating direct revenue.
Financial Overview
| Financial Metric | Value |
|---|---|
| Market Capitalization (Q4 2023) | $136.42 million |
| Cash and Cash Equivalents (Q3 2023) | $78.6 million |
| Research and Development Expenses (2022) | $48.3 million |
Funding Sources
- Initial Public Offering (IPO) proceeds
- Venture capital investments
- Equity financing
- Research grants
Stock Performance
| Stock Performance Metric | Value |
|---|---|
| NASDAQ Ticker | ATHA |
| Stock Price Range (2023) | $1.50 - $4.25 |
| 52-Week Low | $1.22 |
| 52-Week High | $4.75 |
Potential Future Pricing Strategy
Pricing dependent on clinical trial outcomes for lead drug candidate NDX-1017, targeting neurodegenerative disorders.
Research and Development Investment
| Year | R&D Investment |
|---|---|
| 2021 | $41.7 million |
| 2022 | $48.3 million |
| 2023 (Estimated) | $52.6 million |
Valuation Drivers
- Clinical trial progression
- Regulatory approval milestones
- Potential market opportunity for neurodegenerative treatments
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.